At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 8 enrolled
Drug / intervention
Methamphetamine +3 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Novel Drug Combination as a Pharmacotherapeutic for Methamphetamine-Use Disorder
In Brief
A Phase 1 clinical trial evaluating Methamphetamine, Methylphenidate, and 2 other interventions for Methamphetamine Use Disorder. Completed, enrolled 8 participants across 2 sites.
Detailed Summary
This study will evaluate the behavioral effects of methamphetamine during maintenance on placebo, duloxetine, methylphenidate and duloxetine combined with methylphenidate using sophisticated human laboratory methods.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMethamphetamine Use Disorder
CountriesUnited States
CollaboratorsNational Institute on Drug Abuse (NIDA)
Timeline
Phase 1CompletedFinished
2020202120222023202420252026
Enrollment StartSep 2019
First PostedNov 2019
Primary CompletionMay 2021
TodayJul 2026
First PostedNov 26, 2019
Enrollment StartSep 1, 2019
Primary CompletionMay 5, 2021
TodayJul 2, 2026
Enrollment to primary: 1.7 yearsPosted 6.6 years ago
Interventions
Methamphetaminedrug
In each arm, subjects will receive doses of methamphetamine.
Methylphenidatedrug
In each arm, subjects will receive methylphenidate capsules.
Placebo oral capsuledrug
In each arm, subjects will receive placebo capsules.
Duloxetinedrug
Subjects will receive duloxetine capsules in the duloxetine arm.